Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cancer systems biology

Harnessing off-target effects

The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Noncognate effects of the FDA-approved ALK/IGF1R inhibitor ceritinib lead to repurposing its use in ALK-negative non-small-cell lung cancer (NSCLC).

References

  1. 1

    Hu, Q., Sun, W., Wang, C. & Gu, Z. Adv. Drug Deliv. Rev. 98, 19–34 (2016).

    CAS  Article  Google Scholar 

  2. 2

    Chabner, B. A. & Roberts, T.G. Jr. Nat. Rev. Cancer 5, 65–72 (2005).

    CAS  Article  Google Scholar 

  3. 3

    Leeson, P.D. & Springthorpe, B. Nat. Rev. Drug Discov. 6, 881–890 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Hopkins, A.L. Nat. Chem. Biol. 4, 682–690 (2008).

    CAS  Google Scholar 

  5. 5

    Kuenzi, B.M. et al. Nat. Chem. Biol. 13, 1222–1231 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Dang, C.V., Reddy, E.P., Shokat, K.M. & Soucek, L. Nat. Rev. Cancer 17, 502–508 (2017).

    CAS  Article  Google Scholar 

  7. 7

    Vogelstein, B. & Kinzler, K.W. Trends Genet. 9, 138–141 (1993).

    CAS  Article  Google Scholar 

  8. 8

    Robin, X. et al. Clin. Pharmacol. Ther. 94, 646–650 (2013).

    CAS  Article  Google Scholar 

  9. 9

    Lovly, C.M. et al. Nat. Med. 20, 1027–1034 (2014).

    CAS  Article  Google Scholar 

  10. 10

    Tan, D.S.W. et al. J. Thorac. Oncol. 11, 1550–1557 (2016).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Rune Linding.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saginc, G., Voellmy, F. & Linding, R. Harnessing off-target effects. Nat Chem Biol 13, 1204–1205 (2017). https://doi.org/10.1038/nchembio.2519

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing